Novel Emerging Therapies in Relapsed/Refractory AML | Supplements And Featured Publications

Research Efforts Seek to Further Explore the Potential of Uproleselan in AML

April 14, 2022

Tapan M. Kadia, MD, discusses what makes uproleselan unique from other agents under investigation in acute myeloid leukemia and sheds light on the many research efforts dedicated to further exploring its use in this disease.

Uproleselan Plus Chemotherapy Continues to Show Promise in AML

March 17, 2022

The addition of uproleselan to standard chemotherapy improved improve response rates and reduced chemotherapy-induced mucositis in patients with newly diagnosed and relapsed/refractory acute myeloid leukemia in a phase 1/2 trial.